3nd BenBedPhar Scientific meeting
Dr. Gina Manda, Vice-Chair
Welcome to the third BenBedPhar Scientific meeting on NRF2 medicine and therapeutics for fostering the translation of NRF2 research from bed to bench. The transcription factor NRF2 exerts a broad spectrum cytoprotective effects against several pathologic mechanisms comprising low-grade chronic inflammation, metabolic alterations and redox signaling disturbances. Observations from animal models of disease and clinical studies, complemented by systems medicine approaches, suggest common alterations of NRF2 activity in several chronic pathologies including neurodegenerative, cardiovascular, metabolic and autoimmune diseases, along with cancer.
In this scientific meeting, twenty-seven lectures and eight posters will illustrate the intensive work that is being conducted on NRF2 physiopathology. Moreover, promising new or repurposed NRF2-modulating drugs that are found in different phases of preclinical development will be discussed.
National Institute of Pathology, Bucharest, Romania
“Victor Babeș” National Institute of Pathology, Bucharest, Romania .
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
Grant Holder: Universidad Autónoma de Madrid
Start of Action: 19 October, 2021
End of Action: 18 October, 2025
Entry into force: DATE HERE
CSO approval date: 25 May 2021
Action email: firstname.lastname@example.org